Omega-3 supplementation in children with mood disorders is associated with decreased impairment in executive functioning.
Heart rate variability and specific inflammatory biomarkers can differentiate major depressive disorder from depression in bipolar disorder.
Venlafaxine was superior to lithium in reducing symptoms of both bipolar II, depression, and anxiety.
The US Food and Drug Administration has approved Abilify MyCite, which contains an ingestible sensor that records whether or not the medication was taken.
Asenapine shown to decrease the time to recurrence of manic and depressive episodes among patients with bipolar I disorder.
Psychosis was not associated with worse clinical or functional outcomes in patients with bipolar disorder.
Mixed and psychotic features and comorbid anxiety disorder were also associated with poor treatment response.
Individuals with a first manic episode with psychotic features were randomly assigned to receive lithium or quetiapine monotherapy during the randomized controlled trial.
Overall, 54% of women with bipolar disorder reported sexual distress and 39% were not satisfied with their sexual life.
Thyroid disease may be a risk factor for manic relapse in patients with bipolar disorder.
Researchers found that mood relapse episodes were delayed with risperidone long-acting injection.
An earlier diagnosis of depression is associated with having a longer delay in conversion to bipolar disorder.
The response to lurasidone between baseline and 2 weeks indicates later treatment success in bipolar depression.
Cognitive-behavioral therapy effectively lowered the relapse rate and lessened depressive symptoms.
A 36-year-old man with type 1 diabetes presents to the emergency room with hyperglycemia and possible diabetic ketoacidosis after not taking his insulin for 3 days.
Patients with high risk for bipolar disorder are more likely to exhibit decreased cognitive performance as a function of increasing overweight status.
Clinicians should monitor thyroid function when managing patients receiving lithium for bipolar disorder.
Cognitive remediation may aid neurocognitive performance, including attention, working memory, and problem solving in bipolar disorder.
Patients with greater clinical symptom severity had lower quality of life and higher functional impairment.
Reviews containing "wishlists" indicate that consumer needs are not adequately addressed by the apps that are currently available.
The findings show no significant difference among sertraline monotherapy, lithium monotherapy, or a combination of the 2 medications.
No difference was observed in risk of overall cancer in patients with bipolar disorder who use lithium, compared with the general population.
Atypical antipsychotic adjunctive therapy and mood stabilizers may be a more effective treatment than mood stabilizer monotherapy.
Lithium has been the mainstay of treatment for decades, but several other classes of medication have recently been used with varying degrees of success.
The declining rates for lithium use are linked to the burden of side effects and toxicity associated with the drug.
The Mood Zoom questionnaire rates anxiety, elation, sadness, anger, irritability, and energy on a 7-point scale.
Cognitive reserve in bipolar patients gives a possible explanation for the differences seen among patients in their ability to perform in neurocognitive tests.
Researchers observe a cohort effect for earlier age at onset of bipolar disorder. Bipolar disorder is also more common in patients with a family history of unipolar depression and bipolar disorder.
Treatment initiated in the early stages of bipolar disorder is more effective than treatment in later stages.